Dimensional Fund Advisors’s AIM ImmunoTech AIM Stock Holding History

Dimensional Fund Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-836	Closed	-$89K	–	3609
2022 Q1	$89K	Sell	836 -2,180	-72%	-$188K	﹤0.01%	3408
2021 Q4	$277K	Sell	3,016 -694	-19%	-$107K	﹤0.01%	3291
2021 Q3	$749K	Buy	3,710 +2,317	+166%	+$468K	﹤0.01%	3100
2021 Q2	$299K	Buy	+1,393	New	+$298K	﹤0.01%	3258
2015 Q1	–	Sell	-2	Closed	-$26K	–	3561
2014 Q4	$26K	Sell	2 -3	-60%	-$44.8K	﹤0.01%	3407
2014 Q3	$87K	Hold	5	–	–	﹤0.01%	3351
2014 Q2	$86K	Hold	5	–	–	﹤0.01%	3390
2014 Q1	$115K	Hold	5	–	–	﹤0.01%	3369
2013 Q4	$76K	Hold	5	–	–	﹤0.01%	3380
2013 Q3	$68K	Sell	5 -1	-17%	-$12.6K	﹤0.01%	3422
2013 Q2	$65K	Buy	+6	New	+$71.6K	﹤0.01%	3417

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors's AIM Position: Q2 2022 in Review

Dimensional Fund Advisors sold out of AIM ImmunoTech (AIM) in Q2 2022, closing a stake of 836 shares — an estimated $89K sold.

Dimensional Fund Advisors first reported a position in AIM in Q2 2013 and held it in 11 quarters. The position peaked at $749K in Q3 2021. 36 funds tracked by Wall St. Rank hold AIM as of Q2 2022.

Dimensional Fund Advisors reported no remaining AIM ImmunoTech position as of Q2 2022 after selling out during the quarter.
Dimensional Fund Advisors sold 836 AIM ImmunoTech shares in Q2 2022, an estimated $89K.
Dimensional Fund Advisors first reported a position in AIM ImmunoTech in Q2 2013 and held it in 11 quarters.
Dimensional Fund Advisors's AIM ImmunoTech position peaked at $749K in Q3 2021.
36 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2022.

Based on Dimensional Fund Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.